Pharma Focus Asia

Aquavit Pharmaceuticals Launches First-of-its-kind AQUAGOLD® Fine Touch™

Aquavit Pharmaceuticals, Inc. has launched a cutting-edge technology the AQUAGOLD® fine touch. It is a first-of-its-kind direct dermal application technology.

The unique features of the AQUAGOLD® fine touch is that it minimises risks of hurting and swelling in the facial skin. Therefore it makes treatment around the mouth, eyes etc., much easier.  These areas are usually difficult to treat especially under traditional methods of delivery which are available in the market.

This technology is a long-awaited solution for the unmet needs of the more than 11 billion dollar medical aesthetics market and the 30 billion dollar vitamin and mineral market.

Depending on the growing demands of the patients, it can be used with microbotox, hyaluronic acid-based fillers and vitamin combinations as well, according to Dr. David Shafer, Chief Medical Technology Officer of Aquavit Pharmaceuticals.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024